Medibiofarma announces the completion of a new financing round of 2 million euros, with the financial support of its founder team and the incorporation of new partners, among them, Sodena, a public investment entity of the Government of Navarre, which has undertaken a €1-million investment commitment in Medibiofarma with the aim of supporting the development of new therapies in immuno-oncology.

This new investment will enable the advancement of Medibiofarma´s research and development programs including MBF-118, a novel PPAR gamma modulator which will reach clinical development the second half of 2019.

Likewise, Medibiofarma has made a commitment to suppliers in Navarre both for the pharmaceutical development of products as well as for the possibility of conducting initial clinical trials. “This operation not only allows maintaining and retaining a Navarre company but also reinforces it due to its potential for success at the international level, as well as contributing decisively to consolidate the Navarre biotechnological ecosystem in line with the development axis “Healthy Navarre” marked by the Intelligent Specialization Strategy, S3 Navarra” points out Pilar Irigoien, managing director of Sodena.

http://www.sodena.com/index.php/es/sodena-informa/notas-de-prensa/1092-compromiso-de-sodena-de-1-millon-de-euros-en-medibiofarma-para-investigar-y-desarrollar-nuevas-inmunoterapias-en-el-tratamiento-de-tumores.html